214 related articles for article (PubMed ID: 24353168)
21. Intravesical bacillus Calmette-Guérin instillation in non-muscle-invasive bladder cancer: A review.
Saluja M; Gilling P
Int J Urol; 2018 Jan; 25(1):18-24. PubMed ID: 28741703
[TBL] [Abstract][Full Text] [Related]
22. Six essential conditions for bladder-sparing strategies in bacillus Calmette-Guérin unresponsive bladder cancer.
Shariat SF; Enikeev DV; Mostafaei H
Immunotherapy; 2019 Sep; 11(13):1083-1086. PubMed ID: 31385744
[No Abstract] [Full Text] [Related]
23. The role of cancer stem cells in immunotherapy for bladder cancer: An in vitro study.
Özcan Y; Çağlar F; Celik S; Demir AB; Erçetin AP; Altun Z; Aktas S
Urol Oncol; 2020 May; 38(5):476-487. PubMed ID: 32192892
[TBL] [Abstract][Full Text] [Related]
24. Enhancing effect of an inhibitor of nitric oxide synthesis on bacillus Calmette-Guerin-induced macrophage cytotoxicity against murine bladder cancer cell line MBT-2 in vitro.
Yamada H; Matsumoto S; Matsumoto T; Yamada T; Yamashita U
Jpn J Cancer Res; 2000 May; 91(5):534-42. PubMed ID: 10835499
[TBL] [Abstract][Full Text] [Related]
25. Bacillus Calmette-Guerin (BCG): Its fight against pathogens and cancer.
Sfakianos JP; Salome B; Daza J; Farkas A; Bhardwaj N; Horowitz A
Urol Oncol; 2021 Feb; 39(2):121-129. PubMed ID: 33262028
[TBL] [Abstract][Full Text] [Related]
26. Activation of natural killer cells by Bacillus Calmette-Guérin.
Brandau S; Böhle A
Eur Urol; 2001 May; 39(5):518-24. PubMed ID: 11464031
[TBL] [Abstract][Full Text] [Related]
27. Safety and Efficacy of Intravesical Bacillus Calmette-Guérin Immunotherapy in Patients with Non-Muscle-Invasive Bladder Cancer Presenting with Asymptomatic Bacteriuria: A Systematic Review.
Poletajew S; Zapała P; Radziszewski P
Urol Int; 2017; 99(1):1-5. PubMed ID: 28601885
[TBL] [Abstract][Full Text] [Related]
28. Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells.
Brandau S; Suttmann H; Riemensberger J; Seitzer U; Arnold J; Durek C; Jocham D; Flad HD; Böhle A
Clin Cancer Res; 2000 Sep; 6(9):3729-38. PubMed ID: 10999767
[TBL] [Abstract][Full Text] [Related]
29. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.
Li R; Sundi D; Zhang J; Kim Y; Sylvester RJ; Spiess PE; Poch MA; Sexton WJ; Black PC; McKiernan JM; Steinberg GD; Kamat AM; Gilbert SM
Eur Urol; 2020 Sep; 78(3):387-399. PubMed ID: 32143924
[TBL] [Abstract][Full Text] [Related]
30. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
[TBL] [Abstract][Full Text] [Related]
31. Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2.
Yamada H; Matsumoto S; Matsumoto T; Yamada T; Yamashita U
J Urol; 2000 Aug; 164(2):526-31. PubMed ID: 10893638
[TBL] [Abstract][Full Text] [Related]
32. A mathematical model of combined bacillus Calmette-Guerin (BCG) and interleukin (IL)-2 immunotherapy of superficial bladder cancer.
Bunimovich-Mendrazitsky S; Claude Gluckman J; Chaskalovic J
J Theor Biol; 2011 May; 277(1):27-40. PubMed ID: 21334346
[TBL] [Abstract][Full Text] [Related]
33. Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review.
Kamat AM; Li R; O'Donnell MA; Black PC; Roupret M; Catto JW; Comperat E; Ingersoll MA; Witjes WP; McConkey DJ; Witjes JA
Eur Urol; 2018 May; 73(5):738-748. PubMed ID: 29055653
[TBL] [Abstract][Full Text] [Related]
34. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
Lamm D; Brausi M; O'Donnell MA; Witjes JA
Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
[TBL] [Abstract][Full Text] [Related]
35. [Genetic and immunologic determinants of intravesical BCG therapy in non-muscle-invasive urothelial bladder cancer].
Krajewski W; Kołodziej A; Dembowski J; Zdrojowy R
Postepy Hig Med Dosw (Online); 2014 Mar; 68():291-300. PubMed ID: 24662797
[TBL] [Abstract][Full Text] [Related]
36. Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses.
Suttmann H; Riemensberger J; Bentien G; Schmaltz D; Stöckle M; Jocham D; Böhle A; Brandau S
Cancer Res; 2006 Aug; 66(16):8250-7. PubMed ID: 16912205
[TBL] [Abstract][Full Text] [Related]
37. Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review.
Zuiverloon TC; Nieuweboer AJ; Vékony H; Kirkels WJ; Bangma CH; Zwarthoff EC
Eur Urol; 2012 Jan; 61(1):128-45. PubMed ID: 22000498
[TBL] [Abstract][Full Text] [Related]
38. Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette‑Guerin by the modulation of the tumor immune environment.
Hori S; Miyake M; Tatsumi Y; Morizawa Y; Nakai Y; Onishi S; Onishi K; Iida K; Gotoh D; Itami Y; Tanaka N; Fujimoto K
Oncol Rep; 2019 Mar; 41(3):1863-1874. PubMed ID: 30628699
[TBL] [Abstract][Full Text] [Related]
39. Bacillus Calmette-Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections.
Larsen ES; Joensen UN; Poulsen AM; Goletti D; Johansen IS
APMIS; 2020 Feb; 128(2):92-103. PubMed ID: 31755155
[TBL] [Abstract][Full Text] [Related]
40. Genetically regulated response to intravesical bacillus Calmette Guerin immunotherapy of orthotopic murine bladder tumor.
Kadhim SA; Chin JL; Batislam E; Karlik SJ; Garcia B; Skamene E
J Urol; 1997 Aug; 158(2):646-52. PubMed ID: 9224385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]